ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Testosterone Patent Upheld
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Jinzang" data-source="post: 63248" data-attributes="member: 12925"><p>Endo International staved off generic competition to Aveed, its injectable long-acting testosterone replacement therapy. The ruling means Aveed (testosterone undecanoate) won’t face generic competition until March 14, 2027, when the second of the challenged patents at issue in the litigation expires. Both of the patents cover methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels. Aveed brings in about $11 million a year in U.S. revenues, according to Bloomberg Intelligence analyst Elizabeth Krutoholow. Bayer Healthcare Pharmaceuticals manufactures the drug and has licensed the rights to Endo. Aveed competes with several other testosterone replacement products on the market, including AbbVie’s AndroGel and Eli Lilly’s Axiron, Krutoholow said. Unlike some other testosterone products that are patches or gels, Aveed is implanted under the skin. It’s designed to provide replacement testosterone for up to three months before a patient requires another injection.</p><p></p><p><a href="https://www.bna.com/endo-bayer-secure-n57982083805/" target="_blank">Full article</a> available.</p></blockquote><p></p>
[QUOTE="Jinzang, post: 63248, member: 12925"] Endo International staved off generic competition to Aveed, its injectable long-acting testosterone replacement therapy. The ruling means Aveed (testosterone undecanoate) won’t face generic competition until March 14, 2027, when the second of the challenged patents at issue in the litigation expires. Both of the patents cover methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels. Aveed brings in about $11 million a year in U.S. revenues, according to Bloomberg Intelligence analyst Elizabeth Krutoholow. Bayer Healthcare Pharmaceuticals manufactures the drug and has licensed the rights to Endo. Aveed competes with several other testosterone replacement products on the market, including AbbVie’s AndroGel and Eli Lilly’s Axiron, Krutoholow said. Unlike some other testosterone products that are patches or gels, Aveed is implanted under the skin. It’s designed to provide replacement testosterone for up to three months before a patient requires another injection. [URL="https://www.bna.com/endo-bayer-secure-n57982083805/"]Full article[/URL] available. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Testosterone Patent Upheld
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top